Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

For years, people taking one of the world’s most common heart drugs have described the same nagging side effect: sore, aching ...

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its ...

Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes.

Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.

Weight-loss jabs, such as Ozempic and Wegovy, have revolutionised the way we treat obesity in humans, and scientists now want ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and early trials suggest very strong ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...